Ignite Creation Date:
2024-05-05 @ 4:47 PM
Last Modification Date:
2024-10-26 @ 9:24 AM
Study NCT ID:
NCT00319800
Status:
UNKNOWN
Last Update Posted:
2008-03-12
First Post:
2006-04-28
Brief Title:
Second-Line Irinotecan or Gefitinib in Docetaxel Pretreated NSCLC
Sponsor:
Gachon University Gil Medical Center
Organization:
Gachon University Gil Medical Center
Study Overview
Official Title:
A Phase II Study of Second-Line Therapy With Irinotecan or Gefitinib in Docetaxel Pretreated Patients With Non-Small Cell Lung Cancer a New Treatment Strategy According to Clinical Predictors for Response
Status:
UNKNOWN
Status Verified Date:
2008-03
Last Known Status:
ACTIVE_NOT_RECRUITING
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
To determine whether in docetaxel pretreated advanced NSCLC patients with favorable clinical parameters gefitinib can produce different outcomes from patients without favorable clinical parameter treated with irinotecan
Detailed Description:
It has been suggested that some clinical parameters including women no smoking history and a histologic diagnosis of adenocarcinoma are associated with favorable outcomes of gefitinib therapy We will conduct a phase II study in docetaxel pretreated advanced NSCLC patients treated with gefitinib or irinotecan according to these clinical parameters in order to determine whether in patients with favorable clinical parameters gefitinib will produce difference outcomes from patients without favorable clinical parameter treated with irinotecan
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None